[
  {
    "ts": null,
    "headline": "The Score: GM, Macy’s, Novo Nordisk and More Stocks That Defined the Week",
    "summary": "Macy’s  is investigating how hundreds of millions of dollars were hidden by one employee.  The retailer delayed its quarterly earnings after finding that an accounting employee had hidden up to $154 million in corporate delivery expenses over several years.  Macy’s said the person didn’t pocket the amounts in question and declined to say how it uncovered the erroneous bookkeeping entries or how it went undetected by the company’s auditor, KPMG.",
    "url": "https://finnhub.io/api/news?id=654a711f76314c1b0e1432aebb5d0238482b11622fe10fd42b181bc15eb5d5ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732915680,
      "headline": "The Score: GM, Macy’s, Novo Nordisk and More Stocks That Defined the Week",
      "id": 131713927,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Macy’s  is investigating how hundreds of millions of dollars were hidden by one employee.  The retailer delayed its quarterly earnings after finding that an accounting employee had hidden up to $154 million in corporate delivery expenses over several years.  Macy’s said the person didn’t pocket the amounts in question and declined to say how it uncovered the erroneous bookkeeping entries or how it went undetected by the company’s auditor, KPMG.",
      "url": "https://finnhub.io/api/news?id=654a711f76314c1b0e1432aebb5d0238482b11622fe10fd42b181bc15eb5d5ae"
    }
  },
  {
    "ts": null,
    "headline": "Galderma Bets on Skin Drug to Turn Around Pharma Business",
    "summary": "Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.",
    "url": "https://finnhub.io/api/news?id=7d506eac6c36635577ff1987f81204851e80c7f95849e17679e8a0599da2366c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732898160,
      "headline": "Galderma Bets on Skin Drug to Turn Around Pharma Business",
      "id": 131710886,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations.",
      "url": "https://finnhub.io/api/news?id=7d506eac6c36635577ff1987f81204851e80c7f95849e17679e8a0599da2366c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b8c5657e6b2c0c14c261579d8cb8dc73eaeb1588fbffb5fba512e2411473d17d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732897980,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 131774955,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b8c5657e6b2c0c14c261579d8cb8dc73eaeb1588fbffb5fba512e2411473d17d"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Lilly (LLY) Down 5% Since Last Earnings Report?",
    "summary": "Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=29900a55bf38bf4d32993259c27bf51f0c1a8a5fb0634940f5f664f86737413f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732897914,
      "headline": "Why Is Lilly (LLY) Down 5% Since Last Earnings Report?",
      "id": 131710887,
      "image": "https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=29900a55bf38bf4d32993259c27bf51f0c1a8a5fb0634940f5f664f86737413f"
    }
  },
  {
    "ts": null,
    "headline": "November Post-Election Boom: Stocks Soar Before The Holidays, Bitcoin Nears $100k",
    "summary": "US stocks surged post-election, driven by consumer spending and optimism. Financials led gains, while Health Care lagged. Bitcoin soared.",
    "url": "https://finnhub.io/api/news?id=3818832ca29f363c1b14497771fd263b2293b1301da02c65522287df18f26803",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732889782,
      "headline": "November Post-Election Boom: Stocks Soar Before The Holidays, Bitcoin Nears $100k",
      "id": 131711279,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/668600179/image_668600179.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "US stocks surged post-election, driven by consumer spending and optimism. Financials led gains, while Health Care lagged. Bitcoin soared.",
      "url": "https://finnhub.io/api/news?id=3818832ca29f363c1b14497771fd263b2293b1301da02c65522287df18f26803"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=1143062a3f5e1886333d7f72e3b40534712a337884a6af2c05732e0780df798f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732888818,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 131710888,
      "image": "https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=1143062a3f5e1886333d7f72e3b40534712a337884a6af2c05732e0780df798f"
    }
  },
  {
    "ts": null,
    "headline": "Radiopharmaceutical trials face extra complexities due to nuclear red tape",
    "summary": "From additional regulatory requirements to transport refusal, the field of radiopharmaceutical trials can face additional red tape.",
    "url": "https://finnhub.io/api/news?id=73c9bcf7d62a4ed1cb3e8348343fd3ec5b7cd8b0e8ae10fe601c7b97097cfaf6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732879805,
      "headline": "Radiopharmaceutical trials face extra complexities due to nuclear red tape",
      "id": 131704218,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/11/GettyImages-2064405956-scaled.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "From additional regulatory requirements to transport refusal, the field of radiopharmaceutical trials can face additional red tape.",
      "url": "https://finnhub.io/api/news?id=73c9bcf7d62a4ed1cb3e8348343fd3ec5b7cd8b0e8ae10fe601c7b97097cfaf6"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner Global Equity ADR Q3 2024 Report",
    "summary": "The Global Equity ADR composite rose 5.3% gross of fees in the third quarter of 2024, trailing the 6.7% gain in the MSCI ACWI Index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=5152dd68b32970c69eb17c513e40fe059d2a47263d1311f696fcc007b466e7f6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732877700,
      "headline": "Harding Loevner Global Equity ADR Q3 2024 Report",
      "id": 131707951,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171573445/image_171573445.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Global Equity ADR composite rose 5.3% gross of fees in the third quarter of 2024, trailing the 6.7% gain in the MSCI ACWI Index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=5152dd68b32970c69eb17c513e40fe059d2a47263d1311f696fcc007b466e7f6"
    }
  },
  {
    "ts": null,
    "headline": "QUAL: Focusing On High Quality American Companies",
    "summary": "iShares MSCI USA Quality Factor ETF offers quality but limited differentiation. See why QUAL's performance may not justify its elevated price-to-book ratio.",
    "url": "https://finnhub.io/api/news?id=503236e1df72a9d7eb20280c48409924c70a8a6c52266ff2f63056b65da1a704",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732870651,
      "headline": "QUAL: Focusing On High Quality American Companies",
      "id": 131706396,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157582683/image_2157582683.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "iShares MSCI USA Quality Factor ETF offers quality but limited differentiation. See why QUAL's performance may not justify its elevated price-to-book ratio.",
      "url": "https://finnhub.io/api/news?id=503236e1df72a9d7eb20280c48409924c70a8a6c52266ff2f63056b65da1a704"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary",
    "summary": "The Janus Henderson Global Life Sciences Diversified ADR Managed AccountÂ Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=d13820debe5090781df5f64d03a4e6366609fc54e420fcea29eb851f7981fff8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732841400,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary",
      "id": 131700113,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1633433467/image_1633433467.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Janus Henderson Global Life Sciences Diversified ADR Managed AccountÂ Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=d13820debe5090781df5f64d03a4e6366609fc54e420fcea29eb851f7981fff8"
    }
  }
]